eXoZymes (EXOZ) investor relations material

Market opportunity and unmet need

• Nature's potent molecules have been inaccessible due to scarcity and complexity, limiting their use in medicine and health applications.

• Addressable markets include obesity, type 2 diabetes, fatty liver disease, aging, and inflammation, representing hundreds of billions of dollars.

• The global nutraceuticals market is projected to reach $683B in 2026 and $1.15T by 2033, with a 7.7% CAGR.

Technology and platform breakthrough

• Developed a cell-free biomanufacturing platform using AI-engineered enzymes to produce rare natural molecules at scale and high purity.

• Platform enables industrial-scale production (>99% purity) of molecules previously too rare or complex to synthesize.

• AI accelerates enzyme design, reducing pathway development from years to months and enabling rapid analog creation.

Flagship molecule and pipeline

• NCT, the first flagship molecule, activates HNF4α, improving metabolism, fat utilization, and inflammation response.

• Preclinical models show 30-40% body weight reduction, improved mitochondrial function, and liver fat clearance without diet restriction.

• NCT and its analogs target multiple billion-dollar indications and are being positioned for both OTC and pharma markets.

• Cannabinoids, terpenes, and flavonoids are next in the pipeline, leveraging the same platform for new therapeutics.